Phase III Clinical Study on the Efficacy and Safety of Semaglutide and Ozempic® in Patients With Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 496 participants.

Also called NCT07046273

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 496 participants (planned count) (from the registry)
Sponsor
Shandong New Time Pharmaceutical Co., LTD (from the registry)
Registry
  • NCT NCT07046273
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07046273. Randomized; no masking; primary purpose treatment. Start 2025-08-01 (anticipated); primary completion 2028-08-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Phase III Clinical Study on the Efficacy and Safety of Semaglutide and Ozempic® in Patients With Type 2 Diabetes
Condition
Type 2 Diabetes (T2DM)
Intervention (Drug)
F027
Intervention (Drug)
Ozempic®
Lead sponsor
Shandong New Time Pharmaceutical Co., LTD (class: industry)

Record details

Record id
cardio:ct-nct07046273
Content hash
3c8fc7955925a05ea1d7fb9167b1ddf4b9aebca69671795437a5805e3f2ee682